After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, PTGX falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Protagonist Therapeutics Inc is $5.29B. A total of 0.92 million shares were traded on the day, compared to an average of 1.20M shares.
In the most recent transaction, MOLINA ARTURO MD sold 2,712 shares of PTGX for 84.77 per share on Nov 17 ’25. After the transaction, the Chief Medical Officer now owns 81,180 company shares. In a previous transaction on Oct 10 ’25, Waddill William D. sold 12,000 shares at 81.62 per share. PTGX shares that Director owns now total 5,130.
Among the insiders who bought shares, WILLIAM WADDILL acquired of 12,000 shares on Oct 10 ’25 at a per-share price of $67.04. In another insider transaction, Waddill William D. sold 4,000 shares at $64.25 per share on Sep 22 ’25. Company shares held by the Director now total 5,130.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, PTGX has a high of $93.25 and a low of $33.70.
As of this writing, PTGX has an earnings estimate of -$0.56 per share for the current quarter. EPS was calculated based on a consensus of 9.0 estimates, with a high estimate of $0.09 per share and a lower estimate of -$0.78. The company reported an EPS of $1.98 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. PTGX’s latest balance sheet shows that the firm has $326.90M in Cash & Short Term Investments as of fiscal 2021. There were $5.86M in debt and $44.02M in liabilities at the time. Its Book Value Per Share was $10.34, while its Total Shareholder’s Equity was $300.02M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PTGX is Buy with a score of 4.71.
